eFFECTOR Therapeutics (FRA:LWK) Debt-to-Equity : 24.48 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is eFFECTOR Therapeutics Debt-to-Equity?

eFFECTOR Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €18.46 Mil. eFFECTOR Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.17 Mil. eFFECTOR Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €0.76 Mil. eFFECTOR Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was 24.48.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for eFFECTOR Therapeutics's Debt-to-Equity or its related term are showing as below:

FRA:LWK' s Debt-to-Equity Range Over the Past 10 Years
Min: -5.16 Med: 0.91 Max: 24.48
Current: 24.48

During the past 4 years, the highest Debt-to-Equity Ratio of eFFECTOR Therapeutics was 24.48. The lowest was -5.16. And the median was 0.91.

FRA:LWK's Debt-to-Equity is ranked worse than
99.72% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs FRA:LWK: 24.48

eFFECTOR Therapeutics Debt-to-Equity Historical Data

The historical data trend for eFFECTOR Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

eFFECTOR Therapeutics Debt-to-Equity Chart

eFFECTOR Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.10

1.16

5.21

-3.55

eFFECTOR Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial										-4.23	7.93	-5.16	-3.55	24.48

Competitive Comparison of eFFECTOR Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, eFFECTOR Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

eFFECTOR Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, eFFECTOR Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where eFFECTOR Therapeutics's Debt-to-Equity falls into.

eFFECTOR Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

eFFECTOR Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(18.84	+	0)	/	-5.314
	=	-3.55

eFFECTOR Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(18.463	+	0.165)	/	0.761
	=	24.48

eFFECTOR Therapeutics (FRA:LWK) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

eFFECTOR Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of eFFECTOR Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

eFFECTOR Therapeutics (FRA:LWK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » eFFECTOR Therapeutics Inc (FRA:LWK) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

EFTR:USA LWK:Germany

Address

142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075

Website

https://www.effector.com

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).

eFFECTOR Therapeutics (FRA:LWK) Headlines

No Headlines